Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.

Literature DB >> 23066344

Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.

Chris Fellner.

Abstract

Entities: Chemical Disease

Year: 2012 PMID： 23066344 PMCID： PMC3462607

Source DB: PubMed Journal: P T ISSN： 1052-1372

× No keyword cloud information.

40 in total

1. Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'?

Authors: Spyros Retsas
Journal: J R Soc Med Date: 2011-06 Impact factor: 5.344

Review 2. Role of sun exposure in melanoma.

Authors: Gil B Ivry; Christina A Ogle; Elisabeth K Shim
Journal: Dermatol Surg Date: 2006-04 Impact factor: 3.398

3. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.

Authors: M B Atkins; L Kunkel; M Sznol; S A Rosenberg
Journal: Cancer J Sci Am Date: 2000-02

4. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.

Authors: A T Stopeck; A Jones; E M Hersh; J A Thompson; D M Finucane; J C Gutheil; R Gonzalez
Journal: Clin Cancer Res Date: 2001-08 Impact factor: 12.531

5. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors: Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal: Clin Cancer Res Date: 2009-11-24 Impact factor: 12.531

6. Cancer immunotherapy: moving beyond current vaccines.

Authors: Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal: Nat Med Date: 2004-09 Impact factor: 53.440

Review 7. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?

Authors: Caroline Robert; Francois Ghiringhelli
Journal: Oncologist Date: 2009-08-01

Review 8. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.

Authors: Lawrence Fong; Eric J Small
Journal: J Clin Oncol Date: 2008-10-06 Impact factor: 44.544

9. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.

Authors: Jeffrey Weber; John A Thompson; Omid Hamid; David Minor; Asim Amin; Ilan Ron; Ruggero Ridolfi; Hazem Assi; Anthony Maraveyas; David Berman; Jonathan Siegel; Steven J O'Day
Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531

10. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.

Authors: Yvonne M Saenger; Jedd D Wolchok
Journal: Cancer Immun Date: 2008-01-17

55 in total

1. AACR Cancer Progress Report 2015.

Authors: José Baselga; Nina Bhardwaj; Lewis C Cantley; Ronald DeMatteo; Raymond N DuBois; Margaret Foti; Susan M Gapstur; William C Hahn; Lee J Helman; Roy A Jensen; Electra D Paskett; Theodore S Lawrence; Stuart G Lutzker; Eva Szabo
Journal: Clin Cancer Res Date: 2015-10-01 Impact factor: 12.531

Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.

1. Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'?

Review 2. Role of sun exposure in melanoma.

3. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.

4. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.

5. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

6. Cancer immunotherapy: moving beyond current vaccines.

Review 7. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?

Review 8. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.

9. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.

10. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.

1. AACR Cancer Progress Report 2015.

Review 2. Cancer drug development: The missing links.

Review 3. A review of the importance of immune responses in luminal B breast cancer.

Review 4. Immune biomarkers: the promises and pitfalls of personalized medicine.

5. Nanoparticle Design Strategies for Effective Cancer Immunotherapy.

6. What's fueling the biotech engine-2012 to 2013.

7. A survey of breakthrough therapy designations.

Review 8. Targeting the PD-1 pathway: a promising future for the treatment of melanoma.

Review 9. Bending the Cost Curve in Childhood Cancer.

10. The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma.